지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.11
- 수록면
- 559 - 569 (11page)
이용수
초록· 키워드
오류제보하기
Background: 20(S)-Ginsenoside Rh2 (GRh2) has been extensively studied for multifaceted health benefits. However, the anti-melanoma effect of GRh2 remains poorly understood. Herein, the anti-melanoma effects and underlying mechanisms of GRh2 were investigated.
Methods: MTT assays, the EdU staining assay, flow cytometric analysis, the cellular thermal shift assay (CETSA), confocal microscope analysis, molecular docking, molecular dynamics (MD), immunoblotting, a B16F10 cell bearing mouse model were adopted to examine the anti-melanoma effect of mechanism of action of GRh2.
Results: In melanoma cells, GRh2 was found to suppress cell proliferation, arrest cell cycle at G0/G1 phase and evoke apoptosis. GRh2 initiated autophagy and inhibited the activity of mTOR, the autophagy negative regulator, in melanoma cells. Repressing autophagy enhanced the anti-melanoma efficacy of GRh2. Molecular docking, MD and CETSA studies revealed that GRh2 stably bound to Src protein (one of the upstream kinases of STAT3). GRh2 suppressed Src and STAT3 activities, thereof prohibiting STAT3 nuclear translocation in melanoma cells. STAT3 over-activation attenuated the cytotoxic, apoptotic and autophagy inductive effects of GRh2. Additionally, GRh2 suppressed B16F10 tumor growth without inducing obvious toxicity in mice. It downregulated phospho-Src, phospho-STAT3, phospho-mTOR and Mcl-1 protein levels, while elevated cleaved-PARP and LC3B-II protein levels in B16F10 tumors.
Conclusion: GRh2 exerts anti-melanoma effects through suppressing Src/STAT3 signaling. This study advances our understanding on the anti-melanoma mechanism of GRh2 and indicates that the intake of GRh2 has the potential to retard melanoma progression.
Methods: MTT assays, the EdU staining assay, flow cytometric analysis, the cellular thermal shift assay (CETSA), confocal microscope analysis, molecular docking, molecular dynamics (MD), immunoblotting, a B16F10 cell bearing mouse model were adopted to examine the anti-melanoma effect of mechanism of action of GRh2.
Results: In melanoma cells, GRh2 was found to suppress cell proliferation, arrest cell cycle at G0/G1 phase and evoke apoptosis. GRh2 initiated autophagy and inhibited the activity of mTOR, the autophagy negative regulator, in melanoma cells. Repressing autophagy enhanced the anti-melanoma efficacy of GRh2. Molecular docking, MD and CETSA studies revealed that GRh2 stably bound to Src protein (one of the upstream kinases of STAT3). GRh2 suppressed Src and STAT3 activities, thereof prohibiting STAT3 nuclear translocation in melanoma cells. STAT3 over-activation attenuated the cytotoxic, apoptotic and autophagy inductive effects of GRh2. Additionally, GRh2 suppressed B16F10 tumor growth without inducing obvious toxicity in mice. It downregulated phospho-Src, phospho-STAT3, phospho-mTOR and Mcl-1 protein levels, while elevated cleaved-PARP and LC3B-II protein levels in B16F10 tumors.
Conclusion: GRh2 exerts anti-melanoma effects through suppressing Src/STAT3 signaling. This study advances our understanding on the anti-melanoma mechanism of GRh2 and indicates that the intake of GRh2 has the potential to retard melanoma progression.
목차
ABSTRACT
1. Introduction
2. Materials and methods
3. Results
4. Discussion
5. Conclusions
References
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway
Journal of Ginseng Research
2020 .09
-
The ways for ginsenoside Rh2 to fight against cancer: the molecular evidences in vitro and in vivo
Journal of Ginseng Research
2023 .03
-
Ginsenoside Rh2 attenuates microglial activation against toxoplasmic encephalitis via TLR4/NF-kB signaling pathway
Journal of Ginseng Research
2020 .09
-
Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase
Journal of Ginseng Research
2016 .10
-
Ginsenoside Rh2 reduces depression in offspring of mice with maternal toxoplasma infection during pregnancy by inhibiting microglial activation via the HMGB1/TLR4/NF-kB signaling pathway
Journal of Ginseng Research
2022 .01
-
20(S)-ginsenoside Rh2 induces caspase-dependent promyelocytic leukemia-retinoic acid receptor A degradation in NB4 cells via Akt/Bax/caspase9 and TNF-α/caspase8 signaling cascades
Journal of Ginseng Research
2021 .03
-
Advances in the Treatment of Melanoma
대한임상종양학회 학술대회지
2017 .02
-
Characteristics and Treatment of Cutaneous Melanoma of the Foot
Archives of plastic surgery : APS
2016 .01
-
Melanoma : Diagnosis and Treatment of Acral Melanoma
대한임상종양학회 학술대회지
2015 .02
-
Clinicopathologic features and survival outcomes of ocular melanoma: a series of 31 cases from a tertiary university hospital
Journal of Pathology and Translational Medicine
2022 .07
-
Synergistic Effects of Bee Venom and Natural Killer Cells on B16F10 Melanoma Cell Growth Inhibition through IL-4-mediated Apoptosis
대한침구의학회지
2017 .01
-
Melanoma in Iran: a Retrospective 10-Year Study
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Cutaneous Melanoma in Asians
전남의대학술지
2016 .01
-
Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells
Immune Network
2015 .04
-
Primary Pulmonary Malignant Melanoma: An Unexpected Tumor
Tuberculosis and Respiratory Diseases
2015 .01
-
비강 내 소세포형 악성 흑색종의 면역치료 1예
임상이비인후과
2018 .01
-
Melanoma Cell Death Mechanisms
전남의대학술지
2018 .01
-
MicroRNA-328 Inhibits Proliferation of Human Melanoma Cells by Targeting TGFB2
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Frequency of Trauma, Physical Stress, and Occupation in Acral Melanoma: Analysis of 313 Acral Melanoma Patients in Korea
Annals of Dermatology
2021 .01
-
Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
전남의대학술지
2017 .01
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-151-25-02-092102727